Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2017

View Archived Issues

European Commission approves new single-dose delivery option for Repatha

Lanthio Pharma initiates first-in-human trial of MOR-107

Symptom improvement seen with etrolizumab in phase III study

Valeant Pharmaceuticals enters another EGP-437 licensing agreement with EyeGate

Researchers present safety, efficacy data for hydroxychloroquine plus aldesleukin in mRCC

Gilead tests novel non-catalytic site integrase inhibitor GS-9822 in vivo

Sarepta Therapeutics agrees to sell priority review voucher to Gilead Sciences

CureGrail launches with focus on diabetes

Adapt Pharma applies for E.U. approval of naloxone HCl nasal spray

FDA accepts Carbavance NDA for priority review

CohBar's lead candidates show promise in preclinical studies in NASH model

Protalex gives update on studies of PRTX-100 in ITP

Phase II results do not support further development of topical CD-101 for acute VVC

MJFF awards grant to FORMA Therapeutics for Parkinson's research

Pfizer's BLA for inotuzumab ozogamicin granted priority review by FDA

EMA grants orphan drug designation to LYS-GM101 for the treatment of GM1 gangliosidosis

Cellect Biotechnology reports positive final results from clinical trial of ApoGraft

Apitope reports results from phase IIa study of ATX-MS-1467

Trevena reports promising topline phase III data on oliceridine

FDA grants fast track status to Vericel's ixmyelocel-T

Novel Wnt signaling and IL-6 production inhibitors patented by Samumed

NewLink Genetics presents phase I data on HyperAcute Renal immunotherapy in patients with RCC

XBiotech can continue phase III study of Xilonix for treatment of colorectal cancer

VBL Therapeutics reports full results from exploratory phase II study of VB-111

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...